[]

IAP12 Rec'd PCT/PTO 28 AUG 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN KE: Applic	ation of: Heike STROBEL, et al.				
Serial No.: To	be assigned	Art Unit: To be assigned			
Filing Date: C	oncurrently Herewith	Examiner: To be assigned			
For: REDUCT	TION OF SPONTANEOUS MUTA	TION RATES IN CELLS			
Commissioner P.O. Box 1450 Alexandria, V.					
	INFORMATION D	ISCLOSURE STATEMENT			
	uest that the references identified on F officially made of record in accordanc	form PTO-1449 appended hereto be considered by the se with the provisions of 37 CFR 1.97			
[] Copies [X] A copi <u>PCT//</u> Repor	y of the International Search Report w EP2005/002067 is submitted herewith	parent application Serial No			
A. [X]	filing date of the above application	nent submitted herewith is being filed within three months of the or date of entry into the national stage of an international ate of a first Office action on the merits, whichever event			
OR []		nent submitted herewith is being filed before the mailing of a a Request For Continued Examination under 37 C.F.R. 1.114			
fi ar ev (ling date of the above application or	• *			
Si		m of information contained in this Information Disclosure n from a foreign patent office in a counterpart foreign prior to the filing of this statement.			

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information

Disclosure Statement under § 1.97(c) (\$180.00).

IAC 12 Regid PCT/PTO 28 AUG 2006

r a final action under
ore the payment of the
sued on International

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement, and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted.

Frank P. Grassler, Attorney of Record Registration No. 31,164

Date: August 28, 2006 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

19/590829 ISF12 Rec'd PCT/PT028 AUG 2006

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent of fice in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Frank P. Grassler, Attorney of Record Registration No. 31.164

Date: August 28, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-2482

Facsimile: (919) 483-5730

IAP12 Rec's PGT/PTC 2 8 AUG-2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTORNEY DOCKET NO. 1 SERVE 100 829							
				APPLICANT: Heike STROBEL, et al.						
				FILING DATE: GROUP						
					Concurrently Herewith	h	To be assigned	<u> </u>		
U.S. PATENT DOCUMENTS										
Examiner Initlals		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate		
							ļ			
	-			-		<u> </u>	-			
				-			-			
						-				
	_							_		
										
				l						
				ontinue on p						
			FOREIG	V PATENT	DOCUMENTS					
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No		
							<u> </u>			
	_					_	 			
								-		
			Co	ntinue on p	page					
		OTHER DOCUM	1ENTS (Includir	g Author,	Title, Journal-Date, P.	age Numb	er, Etc.)			
	1.	Foster, Patricia, et al., "Proofreading-defective DNA polymerase II increases adaptive mutation in Escherichia coil," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, no. 17, 1995, pp. 7951-7955.								
	2.	Zhao, Jingyong, et al., "Reduction of GC fwdarw TA transversion mutation by overexpression of MutS in Escherichia coli K-12," JOURNAL OF BACTERIOLOGY, vol. 182, no. 17, September 2000, pp. 5025-5028.								
		-								
	_									
			C	ontinue on	page					
EXAMINER	. /J	ennifer Graser/				DATE C	ONSIDERED			
								11/19/2010		
EXAMINER	: Initia	l if citation conside	red, whether or no	ot citation is	s in conformance with M	1PEP § 609	; Draw line thro	ugh citation		
if not in conf	ormano	e and not considere	 d. Include copy of 	of this form	with next communication	on to the ap	plicant.			